Spectrin isoforms: Differential expression in normal hematopoiesis and alterations in neoplastic bone marrow disorders

American Journal of Clinical Pathology

Volumn 136, Issue 2, 2011, Pages 300-308

  Wolgast, Lucia R ^a   Cannizzarro, Linda A ^a   Ramesh, K H ^a   Xue, Xiaonan ^a   Wang, Dan ^a   Bhattacharyya, Pritish K ^b   Gong, Jerald Z ^c   McMahon, Christine ^a   Albanese, Joseph M ^a   Sunkara, Jaya L ^a   Ratech, Howard ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Acute erythroid leukemia; Acute megakaryoblastic leukemia; Acute myeloid leukemia; Embryonic liver fodrin; Myelodysplastic syndrome; Myeloproliferative neoplasm; Spectrin

Indexed keywords

CD34 ANTIGEN; ISOPROTEIN; MYELOPEROXIDASE; SPECTRIN; SPECTRIN ALPHA I ISOFORM; SPECTRIN ALPHA II ISOFORM; SPECTRIN BETA I ISOFORM; SPECTRIN BETA II ISOFORM; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE MEGAKARYOCYTIC LEUKEMIA; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CANCER; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; ERYTHROLEUKEMIA; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEGAKARYOCYTE; MYELOBLAST; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; MYELOPROLIFERATIVE DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; THROMBOCYTHEMIA;

HEMATOPOIESIS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; MYELOPROLIFERATIVE DISORDERS; PROTEIN ISOFORMS; RETROSPECTIVE STUDIES; SPECTRIN; TUMOR MARKERS, BIOLOGICAL;

EID: 79960989837     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPSA5RNM9IGFJF     Document Type: Article

References (32)

1. Bennett V, Gilligan DM. The spectrin-based membrane skeleton and micron-scale organization of the plasma membrane. Annu Rev Cell Biol. 1993;9:27-66.
2. Beck KA. Spectrins and the Golgi. Biochim Biophys Acta. 2005;1744:374-382.
3. Tang Y, Katuri V, Dillner A, et al. Disruption of transforming growth factor-beta signaling in ELF beta-spectrin-deficient mice. Science. 2003;299:574-577. (Pubitemid 36135157)
4. Gascard P, Mohandas N. New insights into functions of erythroid proteins in nonerythroid cells. Curr Opin Hematol. 2000;7:123-129. (Pubitemid 30106545)
5. Brois DW, McMahon LW, Ramos NI, et al. A deficiency in a 230 kDa DNA repair protein in Fanconi anemia complementation group A cells is corrected by the FANCA cDNA. Carcinogenesis. 1999;20:1845-1853. (Pubitemid 29410567)
6. McMahon LW, Sangerman J, Goodman SR, et al. Human alpha spectrin II and the FANCA, FANCC, and FANCG proteins bind to DNA containing psoralen interstrand crosslinks. Biochemistry. 2001;40:7025-7034. (Pubitemid 32554023)
7. Baek HJ, Lim SC, Kitisin K, et al. Hepatocellular cancer arises from loss of transforming growth factor beta signaling adaptor protein embryonic liver fodrin through abnormal angiogenesis. Hepatology. 2008;48:1128-1137.
8. Kim SS, Shetty K, Katuri V, et al. TGF-beta signaling pathway inactivation and cell cycle deregulation in the development of gastric cancer: role of the beta-spectrin, ELF. Biochem Biophys Res Commun. 2006;344:1216-1223.
9. Glasgow E, Mishra L. Transforming growth factor-beta signaling and ubiquitinators in cancer. Endocr Relat Cancer. 2008;15:59-72. (Pubitemid 351449728)
10. Black JD, Koury ST, Bankert RB, et al. Heterogeneity in lymphocyte spectrin distribution: ultrastructural identification of a new spectrin-rich cytoplasmic structure. J Cell Biol. 1988;106:97-109. (Pubitemid 18051397)
11. Pradhan D, Morrow J. The spectrin-ankyrin skeleton controls CD45 surface display and interleukin-2 production. Immunity. 2002;17:303-315. (Pubitemid 35279551)
12. Gorman EB, Chen L, Albanese J, et al. Patterns of spectrin expression in B-cell lymphomas: loss of spectrin isoforms is associated with nodule-forming and germinal center-related lymphomas. Mod Pathol. 2007;20:1245-1252. (Pubitemid 350126851)
13. Liu CL, Prapong W, Natkunam Y, et al. Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 2002;161:1557-1565. (Pubitemid 35265516)
14. De Matteis MA, Morrow JS. The role of ankyrin and spectrin in membrane transport and domain formation. Curr Opin Cell Biol. 1998;10:542-549. (Pubitemid 28391125)
15. Winkelmann JC, Forget BG. Erythroid and nonerythroid spectrins. Blood. 1993;81:3173-3185. (Pubitemid 23172896)
16. Broderick MJ, Winder SJ. Spectrin, alpha-actinin, and dystrophin. Adv Protein Chem. 2005;70:203-246.
17. McMahon LW, Walsh CE, Lambert MW. Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. J Biol Chem. 1999;274:32904-32908. (Pubitemid 129535327)
18. Metral S, Machnicka B, Bigot S, et al. AlphaII-spectrin is critical for cell adhesion and cell cycle. J Biol Chem. 2009;284:2409-2418.
19. Kakhniashvili DG, Chaudhary T, Zimmer WE, et al. Erythrocyte spectrin is an E2 ubiquitin conjugating enzyme. Biochemistry. 2001;40:11630-11642. (Pubitemid 32911308)
20. Kamynina E, Kauppinen K, Duan F, et al. Regulation of proto-oncogenic dbl by chaperone-controlled, ubiquitin-mediated degradation. Mol Cell Biol. 2007;27:1809-1822.
21. Paschka P. Core binding factor acute myeloid leukemia. Semin Oncol. 2008;35:410-417.
22. Tanaka Y, Watanabe T, Chiba N, et al. The protooncogene product, PEBP2beta/CBFbeta, is mainly located in the cytoplasm and has an affinity with cytoskeletal structures. Oncogene. 1997;15:677-683. (Pubitemid 27389930)
23. Serrano E, Carnicer MJ, Lasa A, et al. Epigenetic-based treatments emphasize the biologic differences of core-binding factor acute myeloid leukemias. Leuk Res. 2008;32:944-953.
24. Grand FH, Iqbal S, Zhang L, et al. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy. Exp Hematol. 2007;35:1723-1727. (Pubitemid 47633767)
25. Gallagher G, Horsman DE, Tsang P, et al. Fusion of PRKG2 and SPTBN1 to the platelet-derived growth factor receptor beta gene (PDGFRB) in imatinib-responsive atypical myeloproliferative disorders. Cancer Genet Cytogenet. 2008;181:46-51. (Pubitemid 351200520)
26. Elagib KE, Racke FK, Mogass M, et al. RUNX1 and GATA-1 coexpression and cooperation in megakaryocytic differentiation. Blood. 2003;101:4333-4341. (Pubitemid 36857797)
27. Ohneda K, Yamamoto M. Roles of hematopoietic transcription factors GATA-1 and GATA-2 in the development of red blood cell lineage. Acta Haematol. 2002;108:237-245. (Pubitemid 35356700)
28. Wong EY, Lin J, Forget BG, et al. Sequences downstream of the erythroid promoter are required for high level expression of the human alpha-spectrin gene. J Biol Chem. 2004;279:55024-55033. (Pubitemid 40066494)
29. Muntean AG, Ge Y, Taub JW, et al. Transcription factor GATA-1 and Down syndrome leukemogenesis. Leuk Lymphoma. 2006;47:986-997. (Pubitemid 44102959)
30. Elagib KE, Goldfarb AN. Regulation of RUNX1 transcriptional function by GATA-1. Crit Rev Eukaryot Gene Expr. 2007;17:271-280. (Pubitemid 47015557)
31. Friedman AD. Cell cycle and developmental control of hematopoiesis by Runx1. J Cell Physiol. 2009;219:520-524.
32. Hamlett I, Draper J, Strouboulis J, et al. Characterization of megakaryocyte GATA1-interacting proteins: the corepressor ETO2 and GATA1 interact to regulate terminal megakaryocyte maturation. Blood. 2008;112:2738-2749.